局限期小细胞肺癌61.2Gy同步加量胸部放疗的成熟结局:CALGB 30610/RTOG 0538
该研究报道了CALGB 30610/RTOG 0538中61.2 Gy同步加量(CB)胸部放疗(TRT)组的成熟结局。结论认为CB TRT结局与同期45 Gy每日两次或高剂量每日一次TRT试验相似。
要点
- 61.2 Gy CB TRT组中位OS为32.3个月,5年OS率28.5%。
- 3级和4级非血液学不良事件发生率分别为40.9%和25%。
- CB TRT结局与同期45 Gy每日两次或高剂量每日一次TRT相似。
核心结论
- 61.2 Gy同步加量胸部放疗的结局与同期使用45 Gy每日两次或高剂量每日一次胸部放疗的试验相似,且优于既往II期数据。
研究设计与样本
- CALGB 30610/RTOG 0538是一项随机分配试验,初始阶段按1:1:1分配至45 Gy每日两次、70 Gy每日一次和61.2 Gy同步加量胸部放疗组。
主要发现
- 存活患者中位随访115个月,中位总生存32.3个月(95% CI 20.4-44.8个月),中位无进展生存15.4个月(95% CI 10.0-24.0个月)。
- 5年总生存率为28.5%(95% CI 20.6-39.6)。
- 3级和4级非血液学不良事件发生率分别为40.9%和25%,包括16%吞咽困难和7%严重肺毒性。
临床怎么用
- 61.2 Gy同步加量胸部放疗可作为局限期小细胞肺癌的一种治疗选择,其结局与45 Gy每日两次或高剂量每日一次胸部放疗相似。
局限性
- 同步加量组在计划中期分析后已终止,本研究为该组最大前瞻性数据集但非与标准方案的直接比较。
- 结局改善可能受分期和放疗技术进步等多因素影响,不能完全归因于61.2 Gy同步加量方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report mature outcomes of patients with limited-stage small cell lung cancer randomly assigned to the 61.2 Gy concomitant boost (CB) thoracic radiation therapy (TRT) arm of Cancer and Leukemia Group B (CALGB) 30610/Radiation Therapy Oncology Group (RTOG) 0538. The CB arm was discontinued after planned interim analysis; however, the study provides the largest prospective data set using 61.2 Gy CB TRT. METHODS AND MATERIALS: Eligible patients had limited-stage small cell lung cancer with regional lymph node involvement and Eastern Cooperative Oncology Group performance status 0 to 2. TRT began with either the first or second (of 4 total) cycle of cisplatin-based chemotherapy. Three-dimensional conformal radiation therapy or intensity modulated radiation therapy planning was required. In the initial phase of the trial, patients were randomly assigned with a 1:1:1 allocation to 45 Gy twice daily, 70 Gy once daily, and 61.2 Gy CB TRT. RESULTS: Ninety-three patients were assigned to receive 61.2 Gy CB TRT. After a median follow-up of 115 months for surviving patients, median overall survival and progression-free survival were 32.3 months (95% CI, 20.4-44.8 months) and 15.4 months (95% CI, 10.0-24.0 months), respectively. Five-year overall survival was 28.5% (95% CI, 20.6-39.6). Rates of grade 3 and 4 nonhematologic adverse events were 40.9% and 25%, including 16% dysphagia and 7% severe pulmonary toxicity. CONCLUSIONS: CB TRT outcomes appear similar to contemporaneous trials using 45 Gy twice-daily or high-dose once-daily TRT and compare favorably with prior phase 2 data. Improved outcomes highlight the impact of advances in staging and radiation therapy techniques, although additional factors may have contributed.
引用
- Bogart JA, Wang X, Masters G, et al. Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. Int J Radiat Oncol Biol Phys. 2026. PMID: 42086125. doi:10.1016/j.ijrobp.2026.04.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。